Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 13, 2026, 4:28 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1105–1128 of 2,287 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Fasted State Clear all

Conditions: Healthy, Renal Impairment
Interventions: Calderasib; Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 34 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 2
States / cities: Orlando, Florida • Chicago, Illinois

Conditions: Alzheimer's Disease, Obesity, Diabetes Mellitus
Interventions: Boost (R) 5-2 diet, Healthy Living Diet; Other
Lead sponsor: National Institute on Aging (NIA); NIH
Eligibility: 55 Years to 70 Years
Enrollment: 129 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2022
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Fibrodysplasia Ossificans Progressiva
Interventions: Palovarotene, midazolam; Drug
Lead sponsor: Clementia Pharmaceuticals Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 48 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019
U.S. locations: 1
States / cities: Cambridge, Massachusetts

Conditions: Pain
Interventions: 14C-VX-993; Drug
Lead sponsor: Vertex Pharmaceuticals Incorporated; Industry
Eligibility: 18 Years to 55 Years · Male only
Enrollment: 8 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025
U.S. locations: 1
States / cities: Lincoln, Nebraska

Conditions: Opioid-use Disorder
Interventions: Standard Induction Procedure (SP), Rapid Induction Procedure (RP); Other
Lead sponsor: New York State Psychiatric Institute; Other
Eligibility: 18 Years and older
Enrollment: 415 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 6
States / cities: Orlando, Florida • Rockville, Maryland • Cape Girardeau, Missouri + 3 more

Conditions: Stroke, Gait
Interventions: FastFES; Device
Lead sponsor: customKYnetics; Other
Eligibility: 21 Years to 80 Years
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Newark, Delaware

Conditions: Multiple Sclerosis, Muscle Spasticity, Spinal Cord Injury, Stroke
Interventions: tizanidine hydrochloride capsule; Drug
Lead sponsor: Elan Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002
U.S. locations: 16
States / cities: Tucson, Arizona • Encinitas, California • Northridge, California + 12 more

Conditions: Hypertriglyceridemia With the Metabolic Syndrome
Interventions: Fenofibrate (drug); Drug
Lead sponsor: University of Michigan; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2001 – 2002
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Upper Endoscopy, GLP1-R-related Disease
Interventions: Modified Fasting Guidelines; Other
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Healthy, Type 2 Diabetes, Obesity
Interventions: Dextrose, Clinisol 15%; Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 25 Years to 65 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2026
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Overactive Bladder (OAB) With Symptoms of Frequency, Urgency, and Urgency
Interventions: fesoterodine; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Schizophrenia Disorder
Interventions: Fast Friends, Small Talk; Behavioral
Lead sponsor: University of California, Los Angeles; Other
Eligibility: 18 Years to 65 Years
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Healthy
Interventions: MitoQ, Placebo, MitoTempo, Tempol, L-NAME, SNP - Sodium Nitroprusside; Dietary Supplement · Drug
Lead sponsor: University of Georgia; Other
Eligibility: 18 Years to 75 Years
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2030
U.S. locations: 1
States / cities: Athens, Georgia

Conditions: Diabetes, Diabetes Mellitus, Type 2
Interventions: Faster-acting insulin aspart, Insulin aspart, Insulin degludec, Metformin; Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 18 Years and older
Enrollment: 1,264 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 64
States / cities: Concord, California • Fresno, California • Fullerton, California + 56 more

Conditions: Non-small Cell Lung Cancer
Interventions: Fasting-Mimicking Diet; Other
Lead sponsor: Indiana University; Other
Eligibility: 18 Years to 70 Years
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 3
States / cities: Indianapolis, Indiana

Conditions: Localized Prostate Cancer, Active Surveillance for Prostate Cancer
Interventions: Exercise, Cardiopulmonary Exercise Test (CPET); Behavioral · Other
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years and older · Male only
Enrollment: 104 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2024
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Migraine Headache
Interventions: Stress, Fasting; Behavioral · Other
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years to 65 Years
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Healthy Volunteers
Interventions: Avatrombopag maleate 40 mg; Drug
Lead sponsor: Eisai Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 36 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2013
U.S. locations: 1
States / cities: Tempe, Arizona

Conditions: Healthy Volunteer
Interventions: Venetoclax; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years to 65 Years · Female only
Enrollment: 72 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 2
States / cities: Grayslake, Illinois • Austin, Texas

Conditions: Bladder Cancer, Metastatic Transitional Cell Carcinoma
Interventions: Everolimus; Drug
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 46 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2021
U.S. locations: 1
States / cities: New York, New York

Conditions: Healthy
Interventions: Lansoprazole, Prevacid®; Drug
Lead sponsor: Teva Pharmaceuticals USA; Industry
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2004
U.S. locations: 1
States / cities: Saint Charles, Missouri

Conditions: TBI (Traumatic Brain Injury)
Interventions: Fast MR, Computed Tomography; Procedure
Lead sponsor: University of Colorado, Denver; Other
Eligibility: Up to 72 Months
Enrollment: 225 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Healthy Volunteers
Interventions: 14C-labeled ASP0367; Drug
Lead sponsor: Astellas Pharma Global Development, Inc.; Industry
Eligibility: 18 Years to 55 Years · Male only
Enrollment: 9 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Hypertension
Interventions: DEFINITY® infusion, Human Recombinant Regular Insulin infusion, Dextrose infusion, Flow mediated vasodilation, Endothelial cell collection, Microvascular perfusion assessment using Definity, Microneurography; Drug · Procedure
Lead sponsor: Wanpen Vongpatanasin; Other
Eligibility: 18 Years to 75 Years
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2025
U.S. locations: 1
States / cities: Dallas, Texas

Search by objective public record fields.

A Clinical Study of Calderasib (MK-1084) in Participants With Renal Impairment (MK-1084-010)

Intermittent Calorie Restriction, Insulin Resistance, and Biomarkers of Brain Function

Study Evaluating the Effect of Food on the Pharmacokinetics of Palovarotene and the Effect of Palovarotene on the Pharmacokinetics of the CYP3A4 Substrate Midazolam in Two Cohorts of Healthy Adult Subjects

A Study to Evaluate How the Body Processes 14C-VX-993 After a Single Oral Dose

Surmounting Withdrawal to Initiate Fast Treatment With Naltrexone

FastFES Gait Training for Stroke Patients: Efficacy of Pre-Commercial Device

Comparison of Safety and Efficacy of Tizanidine Hydrochloride Capsules Versus Zanaflex® (Tizanidine Hydrochloride Tablets) Taken While in the Fed State (Just After a Meal) and in the Fasted State (Before a Meal) in Patients With Moderate to Severe Spasticity.

Effects of Micronized Fenofibrate on Fasting and Postprandial Lipoproteins, Inflammatory Mediators and Thrombosis

Effect of Prolonged Fasting Time on Gastric Residual Volume in Patients Taking GLP1 Receptor Agonists

Glucagon Suppression by Hyperglycemia in the Presence and Absence of Amino Acid Infusion

This Is A Study Of Bioavailability And Food Effect For Fesoterodine.

Inter-Brain Synchrony in Schizophrenia

Effects of an Antioxidant Supplement on Blood Vessel Health

Research Study Comparing a New Medicine "Fast-acting Insulin Aspart" to Another Already Available Medicine "NovoRapid"/"NovoLog" in People With Type 2 Diabetes

Fasting-mimicking Diet With Chemo-immunotherapy in Non-small Cell Lung Cancer (NSCLC)

Active Surveillance Exercise Clinical Trial

Acute Stress Response in Migraine Sufferers

A Open-label, Three-period, Partial-replicate Design Study to Evaluate the Inter- and Intrasubject Variability of the Avatrombopag To-be-marketed Formulation Administered as Single Doses of 40 mg to Healthy Subjects Receiving a Low-fat Meal

A Study to Evaluate the Bioavailability and Food Effects of Oral Venetoclax New Tablet Formulation 2.0 in Healthy Adult Female Participants

Everolimus (RAD001) in Metastatic Transitional Cell Carcinoma of the Urothelium

Lansoprazole 30 mg DR Capsule Fasting Replicate Sprinkle Study

Fast MR for Young Children With Traumatic Brain Injury

A Study to Learn How [14C]ASP0367 is Processed by the Body in Healthy Men

Neural Mechanism of Aldosterone-induced Insulin Resistance